Walder Wyss on the closing of Insmed strategic financing

Insmed Incorporated, a global biopharmaceutical company, closed a million strategic financing. The company has announced three strategic financings resulting in aggregate gross proceeds of USD 775 million. Proceeds from the transactions will strengthen Insmed’s financial position, which will place the Company in a position to deliver clinical data from each of its four pillars.

The financing includes a USD 350 million senior secured term loan with funds managed by Pharmakon Advisors, a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds and a USD 150 million secured royalty financing with OrbiMed, a leading investor in the healthcare industry.

Walder Wyss has advised the funds managed by Pharmakon Advisors, BioPharma Credit and OrbiMed. The team was led by Tervel Stoyanov (counsel, pictured) and further included associate Anaëlle Genoud and managing associate Valentin Wiesner, all banking & finance.

Walder Wyss on the closing of Insmed strategic financing



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram